Page 9 - hypertension_newsletter5_draft2

REFLECTIONS
Hypertension
Hypertension Global Newsletter #5 2023

Hypertension

propensity to be highly adherent to the triple combination
(2.38, 95% confidence interval: 2.32–2.44). This was the case CLINICAL PEARLS FROM THE FACULTY
regardless of the sex, age, comorbidities, and number of
co-treatments. Conversely, the risk of being low adherent to
treatment (PDC <25%) involved eight and 23% of the patients
taking the three antihypertensive drugs as SPC and two-
pill combination, respectively. Compared to the three-drug
two-pill combination, patients under three-drug SPC had a
much lower risk of treatment discontinuation (41%, 40–43%,
P<0.001)
WATCH
There was a progressive reduction in the adjusted risk of
hospitalization as adherence increased from very low to high DR. FIKRLE DISCUSS THE CLINICAL
levels. Compared with very low adherence, patients with RELEVANCE OF THIS STUDY
intermediate and high adherence showed an adjusted risk
reduction of CV hospitalizations of 8% (0–15%) and 26%
(20–32%), respectively. CLICK HERE
FOR THE LINK TO FULL ARTICLE
In addition to better adherence, patients on the SPC had
lower mean healthcare costs, largely driven by a reduction
in hospitalization costs, rather than the costs of drugs and
outpatient services which were similar between the two
groups.

In this study, due to the increase in treatment adherence,
SPC reduced the risk of CV outcomes and costs of health
services. The authors concluded that the use of three-drug
SPC can improve CV protection in patients who need more
than two antihypertensive drugs to achieve BP control and
reduce costs for the healthcare system.

TABLE OF CONTENTS